NCT05701956View on ClinicalTrials.gov

Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion

PHASE3RecruitingINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Basilar Artery OcclusionAcute Cerebrovascular AccidentStroke Due to Basilar Artery Occlusion
Interventions
DRUG

Tenecteplase

Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy

PROCEDURE

Endovascular thrombectomy

The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.

Trial Locations (1)

230001

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER